Vesigen Receives National Institutes of Health Award in Targeted Genome Editor Delivery Challenge

Vesigen proposal selected as a “Winning Solution" for programmable delivery systems for gene editing

Proposal builds on recent data demonstrating cell type-specific targeting of Company’s non-viral delivery platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--#ARMMs--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED (Targeted Genome Editor Delivery) Challenge. The Company’s proposal, “Engineered ARMMs: Promising Human-Derived Vectors for Cell Type-Specific Delivery of Genome Editors”, builds on recent data demonstrating directed tropism of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) delivery platform and was among five proposals selected as “Winning Solutions” for programmable delivery systems for gene editing.

“We are honored that the potential to engineer our non-viral ARMMs platform for cell type-specific delivery of gene editing payloads has been recognized by the NIH,” said Joseph Nabhan, Ph.D., Chief Scientific Officer at Vesigen. “The data we have generated demonstrate that ARMMs enable functional delivery of gene editing payloads across a broad range of cell types in vitro and in vivo, and that they can potentially be tailored to selectively target cell types of interest in vivo. We look forward to advancing our platform toward the clinic and unlocking the full potential of genetic medicines.”

The NIH launched the TARGETED Challenge to advance genome editing technology by sourcing innovative solutions for delivering genome editing components safely and effectively. The three-phase challenge supports the NIH's Somatic Cell Genome Editing (SCGE) commitment to developing targeted delivery systems for delivering genome editors to somatic cells in the body.

About Vesigen Therapeutics

Vesigen Therapeutics is a biotechnology company developing a novel, non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen’s patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMs were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.

For additional information visit www.vesigen.com.

Investors and Media:
Adam Bero, Ph.D.
Kendall Investor Relations
abero@kendallir.com